For the first time, new research shows that taking a specific class of migraine medication during the prodromal phase reduces the development and severity of the subsequent headache.
Imaging and other tools that take advantage of developing understanding of migraine pathophysiology could eventually address difficulties in diagnosing and treating the condition.
Triptans, ergots, and antiemetics were ranked as the top three most effective acute migraine medications in an analysis of 10.8 million users' self-reported records.
Intranasal ketamine may offer new hope for people with chronic, refractory migraines where other treatments fail. However, concerns about the addictive nature of the drug may limit its use.